This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for osteoporosis and the supporting scientific evidence and updates the 1996 USPSTF recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and the systematic evidence review on the Web sites already mentioned. Ann Intern Med. 2002;137:526-528 
SUMMARY OF RECOMMENDATIONS
The U.S. Preventive Services Task Force (USPSTF) recommends that women 65 years of age and older be screened routinely for osteoporosis. The USPSTF recommends that routine screening begin at 60 years of age for women at increased risk for osteoporotic fractures (see Clinical Considerations for a discussion of women at increased risk). This is a grade B recommendation. ( The USPSTF makes no recommendation for or against routine osteoporosis screening in postmenopausal women who are younger than 60 years of age or in women 60 to 64 years of age who are not at increased risk for osteoporotic fractures. This is a grade C recommendation. 
CLINICAL CONSIDERATIONS
Modeling analysis suggests that the absolute benefits of screening for osteoporosis among women 60 to 64 years of age who are at increased risk for osteoporosis and fracture are comparable to those of routine screening in older women. The exact risk factors that should trigger screening in this age group are difficult to specify based on evidence. Lower body weight (weight Ͻ 70 kg) is the single best predictor of low bone mineral density (1, 2) . Low weight and no current use of estrogen therapy are incorporated with age into the three-item Osteoporosis Risk Assessment Instrument (1). There is less evidence to support the use of other individual risk factors (for example, smoking, weight loss, family history, decreased physical activity, alcohol or caffeine use, or low calcium and vitamin D intake) as a basis for identifying high-risk women younger than 65 years of age. At any given age, African-American women on average have higher bone mineral density than white women and are thus less likely to benefit from screening.
Among different bone measurement tests performed at various anatomic sites, bone density measured at the femoral neck by dual-energy x-ray absorptiometry is the best predictor of hip fracture and is comparable to forearm measurements for predicting fractures at other sites. Other technologies for measuring peripheral sites include quantitative ultrasonography, radiographic absorptiometry, single-energy x-ray absorptiometry, peripheral dual-energy x-ray absorptiometry, and peripheral quantitative computed tomography. Recent data suggest that peripheral bone density testing in the primary care setting can also identify postmenopausal women who have a higher risk for fracture over the short term (1 year). Further research is needed to determine the accuracy of peripheral bone density testing in comparison with dual-energy x-ray absorptiometry. The likelihood of being diagnosed with osteoporosis varies greatly depending on the site and type of bone measurement test, the number of sites tested, the brand of densitometer used, and the relevance of the reference range.
Clinical Guidelines
Estimates of the benefits of detecting and treating osteoporosis are based largely on studies of bisphosphonates. Some women, however, may prefer other treatment options (for example, hormone replacement therapy, selective estrogen receptor modulators, or calcitonin) based on personal preferences or risk factors. Clinicians should review with patients the relative benefits and harms of available treatment options, and uncertainties about their efficacy and safety, to facilitate an informed choice. No studies have evaluated the optimal intervals for repeated screening. Because of limitations in the precision of testing, a minimum of 2 years may be needed to reliably measure a change in bone mineral density; however, longer intervals may be adequate for repeated screening to identify new cases of osteoporosis. Yield of repeated screening will be higher in older women, those with lower bone mineral density at baseline, and those with other risk factors for fracture.
There are no data to determine the appropriate age to stop screening and few data on osteoporosis treatment in women older than 85 years of age. Patients who receive a diagnosis of osteoporosis fall outside the context of screening but may require additional testing for diagnostic purposes or to monitor response to treatment.
The brief review of the evidence and other sections that are normally included in USPSTF recommendations are available in the complete recommendation and rationale statement on the USPSTF Web site (www.preventiveservices .ahrq.gov).
RECOMMENDATIONS OF OTHERS
In 1998, the National Osteoporosis Foundation, in collaboration with other professional organizations, issued screening guidelines recommending bone density testing for all women 65 years of age or older, as well as younger postmenopausal women who have had a fracture or who have one or more risk factors for osteoporosis (3) . Collaborating groups included the American Academy of Orthopaedic Surgeons, the American College of Obstetricians and Gynecologists, the American Geriatrics Society, the American College of Radiology, the American College of Rheumatology, the American Academy of Physical Medicine and Rehabilitation, the American Association of Clinical Endocrinologists, the Endocrine Society 
